

Gender: Female | Birth year: 1946 | WHO: 0

Tumor: Colorectum (cecum) carcinoma | Lesions: Lung, Peritoneal | Stage: IV

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Recent molecular results

NGS & MSI Panel (15-Jan-2023)

Tumor mutational burden	TMB 8 mut/Mb
Microsatellite (in)stability	Stable
Driver mutations	KRAS G12D

Trial-relevant IHC results

PD-L1	Score < 50%
-------	-------------

Standard-of-care options considered potentially eligible

Treatment	Literature efficacy evidence	Warnings
FOLFIRI	<a href="#">PHASE-3-CRC</a>	
	PFS: 10.0 months (95% CI: 10.0-12.0)	
	OS: 25.0 months (95% CI: 25.0-30.0)	

Phase 2/3+ trials in NL that are open and potentially eligible (0 trials)

None

Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">KRAS-G12D-TRIAL (Phase 1)</a>	KRAS G12D	KRAS G12D	UMC Utrecht	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

Molecular Details

NGS & MSI Panel (15-Jan-2023)

Biopsy location	Lung
Tumor mutational burden	TMB 8 mut/Mb
Microsatellite (in)stability	Stable
Driver mutations	KRAS G12D

IHC results

Ki67	Positive, score 90%
PD-L1	Score < 50%

Molecular history

Event	Description	2023-01-15 NGS & MSI Panel
KRAS G12D (Tier III)	Mutation (cancer-associated variant) Loss of function	VAF 0.2232%
TMB		8.0
MSI		Stable

Efficacy evidence

Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

Treatment	Literature efficacy evidence
FOLFIRI	<a href="#">PHASE-3-CRC</a>
	<b>Patient characteristics:</b>
	WHO/ECOG0: 100, 1: 80, 2: 20, 3: 0, 4: 0
	Primary tumor locationLeft: 145, Both or unknown: 10, Right: 45
	MutationsKRAS exon 2 wild-type 200/200
	Metastatic sitesLiver only: 58 (32.0%), Lung only: 10 (6.0%)
	Previous systemic therapy35/200
	Prior therapiesAdjuvant chemotherapy
	<b>Median PFS:</b> 10.0 months (95% CI: 10.0-12.0)
	<b>Median OS:</b> 25.0 months (95% CI: 25.0-30.0)

PHASE-3-CRC

**Study:** PHASE-3-CRC, Phase III, Adjuvant

**Molecular requirements:** None

**Therapies:** FOLFIRI+Cetuximab, FOLFIRI

**Patient characteristics:**

	Cetuximab + FOLFIRI (n=100)	FOLFIRI (n=200)
Age (median [range])	65.0 [40-75]	65.0 [30-75]
Sex	Male: 50	Male: 120

ACTIN Report (research use only)

PATIENT  
EXAMPLE-CRC-01  
  
REPORT DATE  
17-Sep-2025

	Female: 50	Female: 80
Race	NA	NA
Region	Europe: 100 patients	Europe: 200 patients
WHO/ECOG	0: 80, 1: 10, 2: 10, 3: 0, 4: 0	0: 100, 1: 80, 2: 20, 3: 0, 4: 0
Primary tumor location	Left: 78 Both or unknown: 3 Right: 19	Left: 145 Both or unknown: 10 Right: 45
Mutations	KRAS exon 2 wild-type 100/100	KRAS exon 2 wild-type 200/200
Metastatic sites	Liver only: 62 (62.0%), Lung only: 4 (4.0%)	Liver only: 58 (32.0%), Lung only: 10 (6.0%)
Time of metastases	Unknown	Unknown
Previous systemic therapy	30/100	35/200
Prior therapies	Adjuvant chemotherapy	Adjuvant chemotherapy


Primary endpoints:

	Cetuximab + FOLFIRI	FOLFIRI	Hazard ratio (HR) / Odds Ratio (OR)	P value
Median follow-up for PFS was 70 months				


Secondary endpoints:

	Cetuximab + FOLFIRI	FOLFIRI	Hazard ratio (HR) / Odds Ratio (OR)	P value
Median Overall Survival (95% CI)	35.0 (25.0 - 40.0)	25.0 months (25.0 - 30.0)	0.75 (0.6 - 0.95)	p = 0.011
Median Progression-Free Survival (95% CI)	10.0 (10.0 - 12.0)	10.0 months (10.0 - 12.0)	0.99 (0.8 - 1.25)	p = 1
Median follow-up for PFS was 70 months				


All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report. Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).




y



y





Resistance evidence

Treatment	Mutation	Evidence source	Evidence level	Found in molecular analysis
FOLFIRI	GENE S11C	<a href="#">[1]</a>	D	Yes

Treatment ranking

Event	Treatment	Score
-------	-----------	-------

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report. Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).



ACTIN Report (research use only)

PATIENT  
EXAMPLE-CRC-01  
  
REPORT DATE  
17-Sep-2025

On label clinical evidence

None

Off label clinical evidence

None

Clinical Details

Clinical summary

Relevant systemic treatment history	None	
Relevant other oncological history	11/2021	Hemicolectomy right (Cecum)
Previous primary tumor	Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)	
Relevant non-oncological history	1/2019	Cerebrovascular accident

Patient current details (05-Mar-2023)

Unresolved toxicities grade => 2	None
Known allergies	Morphine
Recent surgeries	12-Nov-2021 Hemicolectomy right

Tumor details (05-Mar-2023)

Measurable disease	Yes
Known lesions	Lung, Peritoneal
No lesions present	CNS, Brain, Liver, Bone

Active medication details

None

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	10-Jan-2023

Trial Matching Details

National trials that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites
<a href="#">KRAS-G12D-TRIAL (Phase 1)</a>	KRAS G12D	KRAS G12D	NL: Utrecht, Germany: Stuttgart

Trials in this table are matched solely on molecular event and tumor type (clinical data excluded).

International trials that are open and potentially eligible (0 trials)

None

Trials and cohorts that are potentially eligible, but are closed (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">METC 01 IEMOEN</a>	<i>Applies to all cohorts below</i>	None		Has not exhausted SOC
	Dose escalation - monotherapy			
	Dose expansion - monotherapy			

Trials and cohorts that are considered ineligible (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Ineligibility reasons
<a href="#">METC 02 KAYRAS</a>	<i>Applies to all cohorts below</i>	KRAS G12D	PD-L1 expression below minimum of 50.0
	Dose expansion - monotherapy - Colorectum		
	Dose expansion - monotherapy - NSCLC		No lung non-small cell carcinoma

Trials and cohorts that are not evaluable or ignored (0 trials)

None

Other trials & cohorts

ACTIN Report (research use only)

PATIENT  
EXAMPLE-CRC-01

REPORT DATE  
17-Sep-2025

METC 02

Potentially eligible **No**  
Acronym **KAYRAS**  
Title **A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer**

Reference	Evaluation
I-05	<b>FAIL</b> PD-L1 expression below minimum of 50.0

METC 02 - Dose expansion - monotherapy - NSCLC

Cohort ID **A**  
Potentially eligible? **No**  
Open for inclusion? **Yes**  
Has slots available? **Yes**

Reference	Evaluation
I-02	<b>FAIL</b> No lung non-small cell carcinoma

METC 02 - Dose expansion - monotherapy - Colorectum

Cohort ID **B**  
Potentially eligible? **No**  
Open for inclusion? **Yes**  
Has slots available? **Yes**

METC 01

Potentially eligible **Yes**  
Acronym **IEMOEN**  
Title **Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors**

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

ACTIN Report (research use only)

PATIENT  
EXAMPLE-CRC-01  
  
REPORT DATE  
17-Sep-2025

Reference	Evaluation
I-03	<div>WARN</div> <div>Has not exhausted SOC</div>
E-01	<div>PASS</div> <div>Has no other condition belonging to category autoimmune disease</div>
E-02	<div>PASS</div> <div>Hemoglobin above 6 mmol/L</div>
E-03	<div>PASS</div> <div>Neutrophils above 1.5</div>
I-01	<div>PASS</div> <div>Patient is at least 18 years old</div>
I-02	<div>PASS</div> <div>Has solid primary tumor</div> <div>Stage IV is considered metastatic</div>

METC 01 - Dose escalation - monotherapy

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	No
Has slots available?	No

METC 01 - Dose expansion - monotherapy

Cohort ID	B
Potentially eligible?	Yes
Open for inclusion?	No
Has slots available?	No